We examined the association between IL28B single-nucleotide polymorphism rs12979860, hepatitis C virus (HCV) kinetic, and pegylated interferon alpha-2a pharmacodynamic parameters in HIV/HCV-coinfected patients from South America. Twenty-six subjects received pegylated interferon alpha-2a + ribavirin. Serum HCV-RNA and interferon concentrations were measured frequently during the first 12 weeks of therapy and analyzed using mathematical models. African Americans and whites had a similar distribution of IL28B genotypes (P = 0.5). The IL28B CC genotype was overrepresented (P = 0.015) in patients infected with HCV genotype-3 compared with genotype-1. In both genotype-1 and genotype-3, the first-phase viral decline and the average pegylated interferon-alpha-2a effectiveness during the first week of therapy were larger (trend P <= 0.12) in genotype-CC compared with genotypes-TC/TT. In genotype-1 patients, the second slower phase of viral decline (days 2-29) and infected cells loss rate, delta, were larger (P = 0.02 and 0.11, respectively) in genotype-CC than in genotypes-TC/TT. These associations were not observed in genotype-3 patients. © 2011 Lippincott Williams & Wilkins.
E.S.A., D. A., H., D., S.J., C., T.J., L., A.U., N., & C.E., M. (2011). Pharmacodynamics of PEG-IFN-alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. Journal of Acquired Immune Deficiency Syndromes, 56(2), 95–99. https://doi.org/http://dx.doi.org/10.1097/QAI.0b013e3182020596